drug development

Biotech By Matthew Herper

FDA approves Lilly diabetes drug that analysts expect to be a big seller

Biotech By Matthew Herper

Pfizer to buy Biohaven for $11.6 billion, raising hopes for the broader biotech market

Special Report By Megan Molteni

From burst bubble to medical marvel: How lipid nanoparticles became the future of gene therapy

Biotech By Ryan Cross — The Boston Globe

Covid shots made Moderna biotech’s biggest star, but what now?

Biotech By Matthew Herper

Researchers describe the human element in the alchemy behind the Moderna vaccine and other new medicines

Biotech By Allison DeAngelis

Despite biotech slump, veterans of SVB and KKR launch investment firm

Biotech By Matthew Herper

Paxlovid’s failure as a preventative measure raises questions, but doctors still back it as a therapeutic

Pharmalot By Ed Silverman

Pharma R&D payments to European researchers are like ‘dark money’

Health By Troy Farah

There’s a new crop of treatments for ADHD in kids. Are they any better?

Opinions+ By Scott Swain, Kristin M. Zimmerman Savill and Bruce Feinberg

Pharma’s role in value-based care starts with value-based research

Special Report By STAT Staff

Covid hasn’t given up all its secrets. Here are 6 mysteries experts hope to unravel

Exclusive By Ed Silverman

Justice Department probes Bausch Health over marketing for dermatology drugs

Health By Angus Chen

Trying not one, but a three-drug combination to help engineered T cells fight cancer

Opinions+ By Marc Herant and Jason Brauner

Incentives to spur repurposing of existing generics for novel uses would open a new paradigm in drug R&D

Health By Angus Chen

Covid vaccines didn’t work for many cancer patients — but researchers are designing a new shot for them

Pharmalot By Ed Silverman

U.K. readies a Netflix-style subscription payment model for badly needed antibiotics

Health By Angus Chen

An mRNA vaccine boost may help CAR T-therapy treat solid cancers

First Opinion By Dennis J. Selkoe and Jeffrey Cummings

CMS made the wrong decision on Aduhelm. But there might be a silver lining

Politics By Rachel Cohrs

Medicare finalizes its restrictions on new Alzheimer’s drug, despite pressure from drugmakers

Pharmalot By Ed Silverman

Advocacy group’s advisory board members defect over Biogen Alzheimer’s drug

The Readout LOUD By Adam Feuerstein and Meg Tirrell

Listen: What’s next for Roche, a debate over second boosters, & Vertex’s recent success

Business By Andrew Joseph

‘We are not casting a wide enough net’: Rob Perez on how biopharma companies can help out their neighbors

Opinions+ By Nicole Paraggio, Nicole van Poppel and Selen Karaca-Griffin

Reimagining R&D can cut drug development costs from billions to millions

Pharmalot By Ed Silverman

Pharma’s ambitious new antibiotic venture fund makes its first investments

Politics By Nicholas Florko

Califf admits controversy over FDA’s Alzheimer’s drug decision impacted experts’ trust in the agency